Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Ascentage Granted US Orphan Drug Status for Leukemia Candidate

publication date: May 5, 2020

Ascentage Pharma of Suzhou was granted Orphan Drug designation in the US for HQP1351, a third-gen BCR-ABL inhibitor aimed at treating drug-resistant chronic myeloid leukemia (CML). The candidate is specifically designed to target BCR-ABL mutants including T315I that cause drug resistance. In July 2019, HQP1351 was cleared by the FDA to start a Phase Ib study in the US. It is currently being tested in a China pivotal Phase II trial, and Ascentage plans to submit a China NDA for HQP1351 this year. More details....

Stock Symbol: (HK: 6855)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.